Fire without smoke: Lung cancer in never-smokers

ONCOLOGY

Volumn 24, Issue 1, 2010, Pages

  Doran, Elizabeth ^a   Jackman, David ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CARBOPLATIN PLUS PACLITAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PACLITAXEL; PROTEIN EML 4; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ASIAN; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PRACTICE; ETHNICITY; GENE MUTATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; REVIEW; RISK FACTOR; SMOKING; TOBACCO; UNITED STATES; WILD TYPE;

EID: 76149101584     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009.
2. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005.
3. Annual smoking-attributable mortality, years of potential life lost, and productivity lossesUnited States, 1997-2001. MMWR Morb Mortal Wkly Rep 54:625-628, 2005.
4. Thun MJ, Henley SJ, Burns D, et al: Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 98:691-699, 2006.
5. Samet JM, Avila-Tang E, Boffetta P, et al: Lung cancer in never smokers: Clinical epidemiology and environmental risk factors. Clin Cancer Res 15:5626-5645, 2009.
6. Nordquist LT, Simon GR, Cantor A, et al: Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest 126:347-351, 2004.
7. Toh CK, Gao F, Lim WT, et al: Never-smokers with lung cancer: Epidemiologic evidence of a distinct disease entity. J Clin Oncol 24:2245-2251, 2006.
8. Fujisawa T, Iizasa T, Saitoh Y, et al: Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol 17:2086-2091, 1999.
9. Yoshino I, Kawano D, Oba T, et al: Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg 81:1189-1193, 2006.
10. Tsao AS, Liu D, Lee JJ, et al: Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106:2428-2436, 2006.
11. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005.
12. Riely GJ, Kris MG, Rosenbaum D, et al: Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14:5731-5734, 2008.
13. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009.
14. Jackman DM, Miller VA, Cioffredi LA, et al: Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials. Clin Cancer Res 15:5267-5673, 2009.